Search results for "Agoni"

showing 10 items of 2493 documents

Platelet Reactivity in Hemophilia a. Flow Cytometry Study to Detect the Hemorragic Phenotype

2016

Abstract INTRODUCTION Hemophilia A (HA) is a rare inherited genetic disorder linked to the X chromosome, characterized by joint bleeding in patients with severe disease with <1% of factor VIII (FVIII)(White et al. Thromb Haemost 2001). However, there are cases of severe HA with less bleeding than usual and it has been postulated that there must be other contributors to the hemorrhagic phenotype, including a platelet dysfunction (Van Bladel et al. Haematologica 2011). In this study we analyzed platelet reactivity in a cohort of 16 male patients with severe HA in prophylactic treatment by flow cytometry. The control group was 15 healthy male subjects. METHODS A longitudinal prospective obs…

Agonistmedicine.medical_specialtyVenipuncturemedicine.diagnostic_testmedicine.drug_classbusiness.industryImmunologyCell BiologyHematologyBiochemistryGastroenterologyFlow cytometryBasal (phylogenetics)Internal medicineStatistical significanceImmunologymedicinePlateletPlatelet activationbusinessWhole bloodBlood
researchProduct

Postnatal alterations of the inhibitory synaptic responses recorded from cortical pyramidal neurons in the Lis1/sLis1 mutant mouse

2006

Mutations in the mouse Lis1 gene produce severe alterations in the developing cortex. We have examined some electrophysiological responses of cortical pyramidal neurons during the early postnatal development of Lis/sLis1 mutant mice. In P7 and P30 Lis1/sLis1 neurons we detected a lower frequency and slower decay phase of mIPSCs, and at P30 the mIPSCs amplitude and the action potential duration were reduced. Zolpidem (an agonist of GABAA receptors containing the alpha1 subunit) neither modified the amplitude nor the decay time of mIPSCs at P7 in Lis1/sLis1 neurons, whereas it increased the decay time at P30. The levels of GABAA receptor alpha1 subunit mRNA were reduced in the Lis1/sLis1 brai…

Agonistmedicine.medical_specialtyZolpidemPyridinesmedicine.drug_classAction PotentialsIn Vitro TechniquesBiologyInhibitory postsynaptic potentialMiceCellular and Molecular NeuroscienceInternal medicinemedicineAnimalsReceptorGABA AgonistsMolecular BiologyCerebral CortexReverse Transcriptase Polymerase Chain ReactionGABAA receptorPyramidal CellsAge FactorsGene Expression Regulation DevelopmentalCell BiologyElectric StimulationMice Mutant StrainsCortex (botany)ZolpidemElectrophysiologymedicine.anatomical_structureEndocrinologyAnimals NewbornInhibitory Postsynaptic Potentialsnervous systemCerebral cortex1-Alkyl-2-acetylglycerophosphocholine EsteraseMicrotubule-Associated Proteinsmedicine.drugMolecular and Cellular Neuroscience
researchProduct

α7 Nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus

2000

The present report provides new findings regarding modulation of gamma-aminobutyric acid (GABA) transmission by alpha7 nicotinic receptor activity in CA1 interneurons of rat hippocampal slices. Recordings were obtained from tight-seal cell-attached patches of the CA1 interneurons, and agonists were delivered to the neurons via a modified U-tube. Application for 6 s of the alpha7 nicotinic receptor-selective agonist choline (or =1 mM) to all CA1 interneurons tested triggered action potentials that were detected as fast current transients. The activity triggered by choline terminated well before the end of the agonist pulse, was blocked by the alpha7 nicotinic receptor antagonist methyllycaco…

Agonistmedicine.medical_specialtyalpha7 Nicotinic Acetylcholine ReceptorInterneuronmedicine.drug_classAction PotentialsIn Vitro TechniquesReceptors NicotinicBiologyHippocampusSynaptic TransmissionCholinechemistry.chemical_compoundGanglion type nicotinic receptorInterneuronsInternal medicinemedicineAnimalsNeurotransmittergamma-Aminobutyric AcidPharmacologyMethyllycaconitineDose-Response Relationship DrugRatsElectrophysiologyEndocrinologymedicine.anatomical_structureNicotinic agonistchemistryBiophysicsAlpha-4 beta-2 nicotinic receptorAcetylcholinemedicine.drugEuropean Journal of Pharmacology
researchProduct

The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspectives.

2013

Glucagon-like peptide-1 is an incretin secreted in response to nutrient ingestion. Derangements in the incretin system may contribute to the onset and progression of hyperglycemia in Type 2 diabetes. Liraglutide is a long-acting human glucagon-like peptide-1-receptor agonist suitable for once-daily administration. Blood glucose- and weightreducing effects, improvements in pancreatic b-cell function and a low risk of hypoglycemic events have been demonstrated with this agent. There is a trend towards improvement in the proinflammatory milieu. Liraglutide also appears to have beneficial effects on plasma lipids and lipoproteins in the form of a reduction in total cholesterol, triglycerides an…

Agonistmedicine.medical_specialtybusiness.industryLiraglutidemedicine.drug_classCholesterolEndocrinology Diabetes and MetabolismIncretincardiovascular risk diabetes lipids lipoproteins liraglutideType 2 diabetesmedicine.diseaseProinflammatory cytokinechemistry.chemical_compoundEndocrinologychemistryInternal medicineDiabetes mellitusmedicinelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessProspective cohort studymedicine.drug
researchProduct

Mechanical impact of the antagonist muscles during maximal dorsiflexion is action mode dependent

2019

Maximal voluntary contraction (MVC) has long been considered as the best measure of neuromuscular performance. However, when MVC is paired with electromyographic (EMG) activity recording it has bee...

Agonistmedicine.medical_specialtybusiness.industrymedicine.drug_classMechanical impactBiomedical EngineeringAntagonistMeasure (physics)BioengineeringGeneral Medicinemusculoskeletal systemCoactivationComputer Science Applicationsbody regionsHuman-Computer InteractionVoluntary contractionPhysical medicine and rehabilitationAction (philosophy)Medicinebusinesshuman activitiesComputer Methods in Biomechanics and Biomedical Engineering
researchProduct

Coactivation at the ankle joint is not sufficient to estimate agonist and antagonist mechanical contribution

2009

The aim of this study was to assess, via an elec- tromyographic (EMG) biofeedback method, the mechanical con- tribution of both agonist and antagonist muscles during maximal voluntary contraction (MVC). We compared this original method with the MVC-EMGmax ratio and the torque/EMG relationship method, both of which are commonly used to estimate antago- nist torque. The plantarflexion (PF) and dorsiflexion (DF) MVCs were measured simultaneously with EMG activity of triceps surae (TS) and tibialis anterior in 15 young adults (mean age 23 years). Antagonist torques obtained from the torque/EMG relationship and EMG biofeedback methods appeared to be similar. TS antagonist torque had a major mech…

Agonistmedicine.medical_specialtymedicine.diagnostic_testPhysiologyChemistrymedicine.drug_classAntagonistBiomechanicsAnatomyElectromyographymusculoskeletal systemCoactivationbody regionsCellular and Molecular NeuroscienceElectrophysiologyPhysical medicine and rehabilitationmedicine.anatomical_structurePhysiology (medical)medicineNeurology (clinical)Anklemedicine.symptomMuscle contractionMuscle & Nerve
researchProduct

Die nächste Generation „atypischer” Antipsychotika: Der Beitrag der Positronenemissionstomographie

2003

Almost fifteen years of research with Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have led to a profound understanding of the relationships between antipsychotic doses and plasma levels on the one hand and occupancy of (striatal) D 2 -like dopamine receptors on the other hand as well as with the associated clinical effects and side effects. Furthermore, with the development of clinically atypical" antipsychotics PET studies helped to generate hypotheses regarding the essential pharmacological properties of this heterogeneous class of drugs. Possible mechanisms of action include combined D 2 -/5-HT 2 antagonism, preferential mesolimbic binding, a…

Agonistmedicine.medical_specialtymedicine.diagnostic_testmedicine.drug_classmedicine.medical_treatmentSingle-photon emission computed tomographyPsychiatry and Mental healthEndocrinologyNeurologyMechanism of actionPositron emission tomographyDopamine receptorIn vivoInternal medicinemedicineAripiprazoleNeurology (clinical)medicine.symptomPsychologyAntipsychoticmedicine.drugFortschritte der Neurologie · Psychiatrie
researchProduct

GABAA agonist muscimol ameliorates learning/memory deficits in streptozocin-induced Alzheimer’s disease non-transgenic rat model

2015

Background: GABAergic inhibitory action regulates learning/memory processes and contributes to neurotransmission (Gong et al., 2009). Existing evidence suggests GABAergic system is involved in pathophysiology of Alzheimer’s disease (AD) via inhibitory interneuron deficits (Verret et al., 2012) and decrease in functional GABAA receptors (Limon et al., 2012). In vitro, GABA and muscimol (GABAA receptor agonist) blocked neuronal death induced by Aβ in rat hippocampal and cortical neurons (Paula-Lima et al., 2005). Our concept: low doses of muscimol may prevent learning/memory deficits in intracerebroventricular (icv) streptozocin (STZ)-induced AD non-transgenic rat model. Methods. Wistar male …

Agonistmedicine.medical_specialtymedicine.drug_class02 engineering and technologyWater mazeNeurotransmissionHippocampal formationInhibitory postsynaptic potential030226 pharmacology & pharmacymemory03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMedicineMultidisciplinarybusiness.industryGABAA receptorstreptozocin021001 nanoscience & nanotechnologymuscimol3. Good healthEndocrinologynervous systemMuscimolchemistryAnesthesiaPoster PresentationGABAergic0210 nano-technologybusinessSpringerPlus
researchProduct

Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2

2019

Resumen: El adecuado tratamiento de la diabetes mellitus tipo 2 (DM2) incluye la alimentación saludable y el ejercicio (150 min/semana) como pilares básicos. Para el tratamiento farmacológico, la metformina es el fármaco de elección inicial, salvo contraindicación o intolerancia; en caso de mal control, se dispone de 8 familias terapéuticas (6 orales y 2 inyectables) como posibles combinaciones. Se presenta un algoritmo y unas recomendaciones para el tratamiento de la DM2. En prevención secundaria cardiovascular se recomienda asociar un inhibidor del cotransportador sodio-glucosa tipo 2 (iSGLT2) o un agonista del receptor de glucagon-like peptide-1 (arGLP1) en pacientes con obesidad. En pre…

Agonistmedicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematologyOverweight:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diabetic Diet [Medical Subject Headings]GastroenterologyDiabetes tipo 2:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]03 medical and health sciences0302 clinical medicineFármacos antidiabéticos:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [Medical Subject Headings]Internal medicineDiabetes mellitusmedicineGliclazide030212 general & internal medicineHiperglucemiaContraindicationlcsh:R5-920business.industryAntidiabetic drugs:Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]nutritional and metabolic diseases:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style [Medical Subject Headings]Type 2 diabetesGeneral Medicinemedicine.diseaseSulfonylureaObesityHumanos:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]MetforminHyperglycemia:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]medicine.symptomlcsh:Medicine (General)Family Practicebusinessmedicine.drug
researchProduct

Study of the Expression of Angiogenic Factors and Dopaminergic Receptors: Correlation with ZAP70, CD38 and the Mutational State in Chronic Lymphocyti…

2006

Abstract The angiogenesis is a well known process implicate in the progression of CLL. In this disease has been described an increase of angiogenic and pro-angiogenic factors in serum and angiogenic receptors in B cells, mainly in advances stages. Recently had been known that the agonist of the dopaminergic receptor D2 can inhibit the tumour growth and a possible mechanism mediator is the internalization of VEGFR-2. The aim of this work had been to analyze the expression of the dopaminergic receptors (D1, D2, D3, D4 and D5), the angiogenic receptors and its correlation with the main biological factor implicated in the illness (ZAP-70, CD38 and the mutational status of IgVH/BCL-6). We had de…

Agonistmedicine.medical_specialtymedicine.drug_classAngiogenesisZAP70Chronic lymphocytic leukemiaImmunologyDopaminergicCell BiologyHematologyBiologyCD38medicine.diseaseBiochemistryEndocrinologyDopamine receptorInternal medicinemedicineReceptorBlood
researchProduct